Overview

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and combined therapy of Capecitabine and Oxaliplatin are currently accepted as a standard therapy among the AGC patients who were performed gastrectomy from the D2 surgery. However, many improvements will be needed in stage IIIB and IV. Combined chemotherapy of Docetaxel, Capecitabine, and Oxaliplatin may be considered as one of the best treatments for IIB and IV(M0) stage AGC patients who were performed gastrectomy.

Phase:

Phase 3

Details

Lead Sponsor:

Asan Medical Center

Collaborators:

Hallym University Medical Center
Inha University Hospital
Seoul National University Bundang Hospital
Severance Hospital

Treatments:

Capecitabine
Docetaxel
Oxaliplatin